ImmuCell (ICCC) Competitors $5.95 +0.03 (+0.51%) Closing price 09/15/2025 03:59 PM EasternExtended Trading$5.96 +0.01 (+0.15%) As of 09/15/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ICCC vs. SGMT, ACIU, SOPH, RAPT, TNXP, VYGR, OGI, AVTE, CRGX, and TLSAShould you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Sagimet Biosciences (SGMT), AC Immune (ACIU), SOPHiA GENETICS (SOPH), Rapt Therapeutics (RAPT), Tonix Pharmaceuticals (TNXP), Voyager Therapeutics (VYGR), Organigram Global (OGI), Aerovate Therapeutics (AVTE), CARGO Therapeutics (CRGX), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. ImmuCell vs. Its Competitors Sagimet Biosciences AC Immune SOPHiA GENETICS Rapt Therapeutics Tonix Pharmaceuticals Voyager Therapeutics Organigram Global Aerovate Therapeutics CARGO Therapeutics Tiziana Life Sciences ImmuCell (NASDAQ:ICCC) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends. Which has better earnings & valuation, ICCC or SGMT? ImmuCell has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuCell$26.49M2.03-$2.16M$0.1931.32Sagimet BiosciencesN/AN/A-$45.57M-$1.83-3.48 Is ICCC or SGMT more profitable? ImmuCell has a net margin of 6.23% compared to Sagimet Biosciences' net margin of 0.00%. ImmuCell's return on equity of 6.25% beat Sagimet Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets ImmuCell6.23% 6.25% 3.87% Sagimet Biosciences N/A -39.88%-38.40% Which has more volatility & risk, ICCC or SGMT? ImmuCell has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.34, indicating that its stock price is 234% more volatile than the S&P 500. Do analysts prefer ICCC or SGMT? Sagimet Biosciences has a consensus price target of $25.67, suggesting a potential upside of 303.56%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than ImmuCell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sagimet Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ICCC or SGMT? In the previous week, Sagimet Biosciences had 4 more articles in the media than ImmuCell. MarketBeat recorded 6 mentions for Sagimet Biosciences and 2 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.29 beat Sagimet Biosciences' score of 0.44 indicating that ImmuCell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of ICCC or SGMT? 13.5% of ImmuCell shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 5.6% of ImmuCell shares are held by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryImmuCell beats Sagimet Biosciences on 8 of the 15 factors compared between the two stocks. Get ImmuCell News Delivered to You Automatically Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ICCC vs. The Competition Export to ExcelMetricImmuCellMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.55M$10.74B$5.80B$10.16BDividend YieldN/A1.86%5.72%4.60%P/E Ratio31.3220.5675.0426.40Price / Sales2.0329.77506.03174.59Price / Cash92.0725.0025.8129.91Price / Book1.933.4313.426.28Net Income-$2.16M$210.63M$3.29B$270.38M7 Day Performance-3.41%-1.46%0.09%1.89%1 Month Performance-2.46%1.65%4.56%6.01%1 Year Performance66.20%-11.43%74.87%25.26% ImmuCell Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ICCCImmuCell1.5059 of 5 stars$5.95+0.5%N/A+63.9%$53.55M$26.49M31.3270Positive NewsHigh Trading VolumeSGMTSagimet Biosciences3.3511 of 5 stars$6.86-2.5%$25.67+274.4%+71.0%$222.93M$2M-3.758News CoverageAnalyst DowngradeACIUAC Immune2.6337 of 5 stars$2.20+0.2%$10.00+353.7%-22.0%$221.30M$31.02M-3.80140Positive NewsSOPHSOPHiA GENETICS2.2512 of 5 stars$3.26-1.8%$8.00+145.4%-20.9%$220.92M$65.17M-7.43520RAPTRapt Therapeutics4.2119 of 5 stars$13.34+0.4%$21.57+61.7%+11.7%$220.63M$1.53M-0.9480News CoveragePositive NewsAnalyst UpgradeTNXPTonix Pharmaceuticals3.3219 of 5 stars$25.16-0.5%$70.00+178.3%+77.0%$220.38M$9.83M-0.6450VYGRVoyager Therapeutics4.037 of 5 stars$3.94-7.6%$13.25+236.6%-32.6%$219.38M$80M-2.14100News CoveragePositive NewsAnalyst ForecastGap UpOGIOrganigram Global1.1088 of 5 stars$1.63-0.9%N/A-8.1%$217.83M$117.47M32.51860AVTEAerovate TherapeuticsN/A$7.48-3.7%N/A-88.4%$216.81MN/A-2.5020Positive NewsHigh Trading VolumeCRGXCARGO Therapeutics1.6611 of 5 stars$4.47flat$15.40+244.5%N/A$216.17MN/A-0.96116News CoverageTLSATiziana Life Sciences0.5552 of 5 stars$1.82+12.3%N/A+83.8%$212.67MN/A0.008News CoverageShort Interest ↑ Related Companies and Tools Related Companies SGMT Alternatives ACIU Alternatives SOPH Alternatives RAPT Alternatives TNXP Alternatives VYGR Alternatives OGI Alternatives AVTE Alternatives CRGX Alternatives TLSA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ICCC) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuCell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
